Loading clinical trials...

Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo | Clinical Trials | Clareo Health

TERMINATEDPHASE2/PHASE3

Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo

A Double-blind, Randomized, Placebo-controlled, Multi-center, Phase II/III Study to Evaluate the Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19

NCT04521296•Daewoong Pharmaceutical Co. LTD.

View on ClinicalTrials.gov

Summary

To evaluate the efficacy and safety after administration of DWJ1248 in patients with mild to moderate COVID-19 compared to the placebo.

Eligibility

Age

19 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Adults over the age of 19 as of the signed date in written consent
•Subjects with mild or moderate COVID-19 according to RT-PCR test (Total score of NEWS is 0-6 or if one item is 3 points)
•Subjects who have symptoms within 7 days or 72 hours after diagnosis

Exclusion Criteria

•Subjects who cannot orally administer the investigational products
•Subjects who need administration of immunosuppressants
•Subjects who are allergic or sensitive to investigational products or its ingredients
•Subjects who have a history of drug and/or alcohol abuse within 52 weeks before screening
•Subjects who have been identified with uncontrolled concomitant diseases or conditions, including significant mental illness and social conditions, that may affect compliance with clinical trial procedures according to the determination of the investigators

Locations (1)

Seoul National University Hospital

Seoul, South Korea

Key Dates

Start Date

September 11, 2020

Primary Completion Date

September 14, 2021

Completion Date

March 18, 2022

Last Updated

June 15, 2022

Enrollment

432

ACTUAL participants

Conditions

Mild to Moderate COVID-19

Interventions

Part 1

OTHER

Part 2

OTHER

A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients

NCT05941793

Mild to Moderate COVID-19

View study

TERMINATEDPHASE2/PHASE3

JT001 (VV116) for the Early Treatment of COVID-19

NCT05242042

Mild to Moderate COVID-19

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 15, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions